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Aim: Head and neck squamous cell carcinomas (HNSCC) are solid tumors with low 
overall survival (40–60%). In a move toward personalized medicine, maintenance of 
tumor biopsies in microfluidic tissue culture devices is being developed. Methodology/
results: HNSCC (n = 15) was dissected (5–10 mg) and either analyzed immediately 
or cultured in a microfluidic device (37°C) for 48 h. No difference was observed in 
morphology between pre- and postculture specimens. Dissociated samples were 
analyzed using trypan blue exclusion (viability), propidium iodide flow cytometry 
(death) and MTS assay (proliferation) with no significant difference observed 
highlighting tissue maintenance. Computational fluid dynamics showed laminar flow 
within the system. Conclusion: The microfluidic culture system successfully maintained 
HNSCC for 48 h, the culture system will allow testing of different treatment modalities 
with response monitoring.
Lay abstract: Head and neck cancers often have a poor treatment outcome. In order 
to study the response of the tissue, a miniaturized culture system has been developed 
to keep a small piece of tumor alive. In the current study, we show that small pieces of 
cancer tissue can be maintained in the system, using tissue structure and viability of 
single cells as a guide. In future work, patient equivalent treatments can be applied to 
these microculture systems to investigate individual patient tumor responses, which 
could help to guide treatment selection.
First draft submitted: 6 December 2016; Accepted for publication: 19 January 2017; 
Published online: 7 March 2017
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Head and neck cancers are a diverse group 
of malignancies arising from cells within the 
mucosal surfaces of the oral cavity, pharynx, 
larynx, salivary glands and nasal cavities [1] 
and are the sixth most common solid tumor 
worldwide [2] with squamous cell carcinomas 
(head and neck squamous cell carcinomas 
[HNSCC]) constituting 90% [3]. A significant 
proportion of patients present with regional 
nodal involvement (40%) and a further 10% 
present with the additional complication of 
distant metastasis [4]. Chemoradiation is the 
predominant primary treatment, but despite 
multiple advances over recent years, such 
as the introduction of intensity-modulated 
radiotherapy [5,6], treatment resistance is a 
persistent problem, contributing to the low 
overall 5-year survival figures of 40–60% 
for patients treated with  radiotherapy or 
 chemoradiotherapy [7].
As a result, the desire for targeted 
approaches to treatment has intensified 
[8,9]. However, to date cetuximab (the anti-
EGFR antibody) is the only approved tar-
geted therapy for the treatment of recur-
rent metastatic head and neck disease [10]. 
Median duration of locoregional control 
was extended by 9.5 months with cetux-
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imab plus radiotherapy compared with radiotherapy 
alone [11]. In addition, searches for biomarkers to aid 
treatment selection have proved challenging with no 
standard-of-care biomarkers currently in use in all 
centers [12].
The human papilloma virus (HPV) is an important 
etiological agent in some subsets of HNSCC, with 
HPV-positive cancers having been shown to have a 
better prognosis and response to therapy than their 
HPV-negative counterparts [13,14]. HPV status is the 
strongest predictor of overall and disease-specific sur-
vival, as well as locoregional control [15]. Therefore, 
in a few centers, high-risk HPV variants are initially 
screened for positivity by p16 immunohistochemistry 
followed by PCR and/or in situ hybridization, in order 
to direct Phase III treatment de-escalation trials [4]. 
Beyond this, no technologies or screening methodolo-
gies to personalize therapy specifically to individual 
patients exist.
A large range of model systems exist to study tumor 
biology and treatment response including cell cul-
ture, spheroids, organoids and mouse models. While 
these methodologies have facilitated advancement of 
the field, they also have associated pitfalls; the use of 
a single cell type or even multiple cell types underes-
timates the complex nature of the in vivo microenvi-
ronment comprising numerous cell types in a unique 
spatial arrangement within an extracellular matrix [16]. 
Three-dimensional culture aims to recapitulate the 
spatial arrangement of cells yet still lacks complexity, 
including the full gamut of cell types such as tumor-
infiltrating lymphocytes [17]. Xenograft models pro-
vide continuous flow to engrafted tumors within an in 
vivo environment, however, procedures are costly and 
lengthy and have clear ethical considerations [18], par-
ticularly at a time when there are calls for a reduction 
in the use of animals in research.
Microfluidic culture systems involve the continuous 
perfusion and removal of waste from a tissue sample ex 
vivo, in a fashion mimicking the function of the circu-
latory system [19]. Multiple pieces from the same initial 
tissue sample can be perfused in parallel devices allow-
ing the study of a range of variables with replicates. 
This provides a potential low-cost method for investi-
gating the biology of patient samples and response to 
therapeutic assault in a personalized fashion.
Microfluidics has been defined as ‘the science and 
technology of systems that process or manipulate small 
(10-9–10-18 liters) amounts of fluids, using channels with 
dimensions of tens to hundreds of micrometres’ [20]. The 
small channel geometries afford the benefit of lami-
nar flow within devices allowing a high level of spatial 
control. Laminar flow is defined at Reynolds numbers 
(Equation 1) below 2000 [21].
Re viscousforce
inertia force VDh
n
t= =
Equation 1: Equation used to generate the Reynolds 
number within a microfluidic device, where ρ (kg/
m3) is fluid density, μ is dynamic viscosity of fluid 
(kg/m/s), D
h
 (m) is the hydraulic diameter and V (m/s) 
is velocity.
Fluid flow modeling of devices by computational 
fluid dynamics (CFD) can afford benefits in the visu-
alization of the properties discussed above, allow-
ing manipulation of designs to achieve the closest 
possible resemblance of the in vivo environment for 
the biomedical model. CFD application in biomedi-
cal devices is relatively recent with more traditional 
applications being found in chemical and mechanical 
 engineering [22].
The dawn of microfluidic applications in tissue cul-
ture began in 2003 with the culture of rat brain tissue 
slices [23], more recently (since 2013), various devices 
have been developed for the culture of human (Table 1) 
and animal tissue [24–28] with the potential of monitoring 
the response to therapeutic assault or external stimuli.
The capability of monitoring tissue response on an 
individual basis using microfluidic technology hopes 
to address the clinical problem of treatment resistance 
(Figure 1). The field has received some scepticism regard-
ing the use of these devices for tissue maintenance with 
questions arising over sample viability and the relevance 
of the data obtained to the in vivo environment [29].
The aim of the current study was to address the uncer-
tainty within this exciting field by generating sound evi-
dence for the maintenance of malignant tissue within 
the microfluidic culture device, without loss of sample 
viability. Herein, flow cytometry is used to determine cell 
death within HNSCC samples before and after micro-
fluidic culture; this is the first time these techniques have 
been used in conjunction to assess primary patient tissue. 
In addition, the in-house-designed microfluidic culture 
device was modeled for fluid flow dynamics.
Materials & methods
Patient biopsies
Tumor tissue samples (n = 15) were obtained from 
patients with HNSCC in accordance with the Local 
Research Ethics Committee (LREC-10/H1304/6) 
and NHS R&D approval (R0897), following written 
informed consent. Patients with no history of previ-
ous treatment undergoing resection surgery, to remove 
either laryngeal, oropharyngeal or oral cavity tumors 
staged at T2–T4 were recruited; associated metastatic 
lymph nodes staged at N1–N2 were also collected 
where possible. Fresh tissue samples were processed 
and cultured within 90 min of excision.
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Table 1. Published literature on the use of microfluidics for ex vivo tissue culture from human samples (1 January 2013 
to 1 November 2016).
Tissue Summary of work conducted Ref.
Intestinal sections (small 
or large bowel)
A dual-flow microfluidic device maintained full thickness intestinal tissue in known 
orientation for up to 3 days. The device perfused luminal and serosal sides independently. 
Tissue maintenance was demonstrated by LDH release, H&E and Ki67 staining. ELISAs were 
conducted on system effluents for Calprotein (s100a8; inflammatory marker)
[30]
Prostate and ovarian 
cancer xenograft and 
primary serous ovarian 
cancer
‘Spheroid-sized’ MDTs (380 μM diameter and 300 μM height) were maintained in a 
microfluidic device with regular medium replacement for up to 8 days. Viability was 
determined on chip by confocal microscopy and off-chip by flow cytometry on dissociated 
cells (annexin V and 7AAD, xenograft only). A proof of concept experiment showed 
carboplatin chemosensitivity testing on a primary ovarian cancer tissue
[31]
Human adipose tissue 3-mm diameter hAT biopsies maintained for up to 7 days were used to study insulin 
resistance in Type 2 diabetes mellitus patients compared with healthy controls. Viability was 
evaluated by MTT assay and morphology shown by off-chip H&E staining. Glucose uptake 
was used as a measure of insulin resistance
[32]
HNSCC Culture of HNSCC biopsies (5–10 mg) for 6 days was used to analyze the response of tissue 
to irradiation (2–40 Gy). Cell death was measured by detection of LDH in the effluent, and 
immunohistochemistry for cleaved cytokeratin-18 was used to calculate an apoptotic index
[33]
Prepuce and occipital 
and temporal scalp skin 
follicular unit extracts
Culture device was developed to prolong culture period of skin biopsies and skin 
equivalents. Punched biopsies (5 mm) of prepuce and ex vivo FUEs were cultured 
separately in the device for 14 days. Samples were taken from the device and cryosectioned 
for downstream analysis of morphology (H&E staining) and immunofluorescence for 
proliferation (Ki67) and apoptosis (TUNEL)
[34]
HNSCC HNSCC biopsy tissue (5–10 mg) maintained for up to 9 days was used to allow testing 
of multiple chemotherapy agents (Cisplatin, Fluorouracil and Docetaxel) alone and in 
combination. Response was measured in the system effluent; cell death was analyzed by 
LDH and viability was measured by WST-1 proliferation assay
[35]
7AAD: 7-Aminoactinomycin D; FUE: Follicular unit extract; Gy: Gray; hAT: Human adipose tissue; H&E: Hematoxylin and eosin; HNSCC: Head and neck squamous 
cell carcinoma; LDH: Lactate dehydrogenase; MDT: Microdissected tissue; MF: Microfluidic; MTT: 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide; 
TUNEL: Terminal deoxynucleotidyl transferase dUTP nick-end labeling; WST: Water-soluble tetrazolium salt.
Microfluidic device & culture system
The microfluidic device was fabricated from two layers 
of thermally bonded B270 glass in the Department of 
Chemistry at the University of Hull (Figure 2A), the 
upper layer was 3 mm in depth and lower glass layer 
1 mm. One inlet hole, one outlet hole and the central 
tissue chamber were drilled into the upper layer corre-
sponding to channels (170 μm wide and 70 μm deep) 
in the lower glass layer, fabricated by photolithogra-
phy and wet etching techniques [36]. Over the central 
well, a PEEK plastic microport was bonded with epoxy 
adhesive, into which an English threaded adaptor 
(both IDEX Kinesis, Cambridgeshire, UK), filled with 
polydimethylsiloxane (Dow Corning, Barry, UK), was 
screwed to seal the chamber.
ETFE tubing (IDEX Kinesis, ) with an inter-
nal diameter of 0.5 mm was secured to the inlet and 
outlet hole by epoxy adhesive and a graphite ferrule 
(Figure 2A; IDEX Kinesis). Dulbecco’s Modified 
Eagles Medium (DMEM; Lonza, Slough, UK) con-
taining 25 mM HEPES (4-(2-Hydroxyethyl)pipera-
zine-1-ethanesulfonic acid) buffer and 4.5 g/l glucose 
supplemented with 10% [v/v] fetal bovine serum 
(Labtech, East Sussex, UK), penicillin/streptomycin 
0.1 U/ml and 0.1 mg/ml, respectively, 0.1 mM NEAA 
(nonessential amino acids), 2.5 μg/ml Amphotericin B 
and 2 mM L-glutamine (All Lonza; hereafter referred 
to as complete medium) was connected to the ETFE 
inlet tubing via a 2-part adapter (Lab smith, CA, 
USA). A 5–10-mg HNSCC sample was placed into 
the central tissue chamber and the system was con-
nected to a Harvard PhD 2000 syringe pump (Har-
vard, UK), the device and tubing were maintained at 
37°C inside an incubator with pressure-driven flow of 
complete medium at a volumetric flow rate of 2 μl/min 
(Figure 2B). Each device was run for 48 h with effluent 
collected in 1.5-ml Eppendorf tubes.
Frozen tissue embedding & morphological 
analyses
Tumor sample was embedded in Tissue-Tek OCT 
(Optimum Cutting Temperature; Sakura, Berkshire, 
UK), by freezing in liquid nitrogen-cooled 2-methyl 
butane (Sigma-Aldrich, Dorset, UK) both prior to 
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and following microfluidic culture. Tissue sections of 
8 μM were cut on a Leica CM1100 Cryostat and fixed 
for 20 min in -20°C cooled methanol, stained in Har-
ris’ Hematoxylin (Sigma-Aldrich) for 5 min before dif-
ferentiating in 1% acid alcohol (concentrated HCl in 
70% Ethanol) and rinsing in running tap water. The 
tissue was then stained with 1% (w/v) Eosin Y (Sigma-
Aldrich) in tap water for 5 min before washing in tap 
water. The tissue was dehydrated through graded alco-
hols (70, 90 and 100%) and three changes of histoclear 
before mounting in histomount. Slides were visualized 
using light microscopy (Nikon ECLIPSE E800) and 
photographed (Micropublisher 5.0 Real Time View-
ing) utilizing Image-Pro premier software (MediaCy-
bernetics, Cambridge, UK). Detailed observations of 
the tissue characteristics were carried out under close 
supervision of a consultant head and neck pathologist, 
Lazslo Karsai.
Tissue dissociation
Dissociation of tumor tissue prior to and following 
microfluidic culture was achieved using a combination 
of mechanical and enzymatic methods; samples of a 
known weight were placed into a secured lid of a 1.5-ml 
Eppendorf tube under aseptic conditions and minced 
using a criss-cross cutting action. Complete medium 
(1 ml) containing 0.02% (w/v) Collagenase IV (Sigma-
Aldrich) and 0.02% (w/v) DNase I (Roche, Hertford-
shire, UK) was added to the Eppendorf tube and the lid 
containing the minced tissue was replaced before incu-
bation on a rotator for 2 h at 37°C and 5% CO
2
. Fol-
lowing enzyme incubation, the suspension was strained 
(70-μm cell strainer, BD, Oxford, UK) and centrifuged 
at 400× g for 5 min, the pellet was resuspended in 1 ml 
of complete medium and percentage viability of tissue 
determined using Trypan Blue exclusion.
Propidium iodide flow cytometry
The resultant cell suspension from the dispersal of a 
single 5–10-mg tissue sample (n = 8) prior to and after 
microfluidic culture was washed in phosphate-buff-
ered saline (PBS; 5 ml) containing 0.25% (w/v) BSA 
(Bovine Serum Albumin; Sigma-Aldrich) and 0.06% 
(w/v) sodium azide (Sigma-Aldrich; PBS/BSA/Azide) 
and divided between two tubes before centrifugation 
at 400× g for 5 min. Pellets were resuspended in 100-
μl PBS/BSA/Azide, and either stained with 500-μg/
ml propidium iodide (PI; Sigma-Aldrich) for 15 min in 
the dark and or remained unstained as a control. 
Following a further wash, the cells were resuspended in 
300-μl PBS/BSA/Azide and analyzed in the FL-3 chan-
nel on a flow cytometer (BD FACSCalibur), a mini-
mum of 10,000 events were acquired and a histogram 
was plotted to determine the percentage of dead cells.
MTS proliferation assay
Metabolic activity/proliferation of dissociated cells 
prior to and following microfluidic culture was deter-
mined using the Promega CellTiter 96® AQueous One 
Solution (Promega, Southampton, UK) according to 
the manufacturer’s instructions. Briefly, dissociated 
cells from a single 5–10-mg tissue were resuspended in 
200 μl of complete DMEM. The suspensions were cul-
tured in duplicate overnight in a 96-well flat-bottomed 
plate before the MTS assay reagent (20 μl) was added 
to each well for 2 h at 37°C prior to measuring absor-
bance of the formazan product at 492 nm (Thermo 
Scientific Multiskan FC, Thermo Scientific, Hamp-
sted, UK). Absorbance values were standardized per 
milligram of starting weight of tissue.
Statistics
Statistical analyses were performed using SPSS statis-
tics 23 (IBM, Portsmouth, UK) and p-values <0.05 
were considered significant. Differences between the 
preculture and postculture samples were tested for 
 significance using independent samples’ t-tests.
Fluid flow modeling
Generally, fluid dynamics is described by governing 
equations [37]:
Conservation of mass equation:
u 04$ =  
where u is flow velocity vector.
Conservation of momentum equation for incompress-
ible fluid:
dt
du
4$t v=
where ρ is density, t is time, σ is total stress;
σ = -pI + 2ηD
where p is pressure, η is dynamic viscosity, D is rate of 
strain tensor, I is identical matrix:
uu )(D 2
1 T4 4= +7 A
where T shows the transpose operation.
Computer simulation of pressure-driven Poiseuille 
flow in the chip was realized using COMSOL soft-
ware, version 5.2a (COMSOL, Cambridge, UK). 
The discretization of governing partial differential 
equations was made by the finite element method. 
Rheological (flow) parameters of the DMEM medium 
were assumed to be the same as water (temperature = 
37°C). The meshing was performed using the phys-
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ics-controlled method with normal-sized triangle ele-
ments from 0.003 to 0.1 mm, the total number of ele-
ments was 14,736. The inlet flow rate was set as an 
inlet boundary condition, and the volumetric flow rate 
of 2 μl/min was transformed with regard to the inlet 
width of 0.5 mm. At the outlet, p = 0 is established.
Navier-Stokes governing equations for incompress-
ible steady-state flow real geometry of the chip were 
solved using COMSOL Multiphysics modelling soft-
ware to obtain velocity field and flow pattern for New-
tonian fluid. The built-in ‘Laminar flow’ module for 
Newtonian fluid (constant dynamic viscosity) was 
selected to simulate fluid flow at given conditions.
Results
Tumor characteristics of patient biopsies, tumor site, 
T and N classification and patient age and gender were 
collected (n = 15; Supplementary Table 1).
Morphological analyses
Hematoxylin and eosin (H&E)-stained HNSCC tis-
sue sections were visualized before placement of the 
tumor in the microfluidic culture device (Figure 3, 
left panel) and following 48 h of continuous perfusion 
within the device (Figure 3, right panel).
Representative images are shown from two patients 
with laryngeal squamous cell carcinoma (A & B). The 
Figure 1. Schematic diagram showing the parallel nature of the on-chip treatment testing concept. Ex vivo testing 
of tissue response provides potential for the selection of treatment on an individual patient basis.
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low-magnification (100×) images show maintenance of 
the tissue structure. Infiltrating islands and intercon-
nected cords of tumor cells are shown in the premicro-
fluidic culture images and are retained following 48-h 
culture. Pale pink stromal areas of the tumor are also 
apparent before and after microfluidic incubation.
The higher magnification (400×) allows the assess-
ment of cellular characteristics and shows an intact 
basement membrane following microfluidic culture. 
Furthermore, the orientation of cell maturation seen 
in premicrofluidic culture tissue, with more mature 
cells observed in the center of tumor islands and nests 
was also present post-48-h microfluidic culture. The 
chronic inflammatory mononuclear cell fraction (lym-
phocytes and macrophages) within the stroma was rec-
ognizable both before and after microfluidic culture.
Viability analyses
No significant difference in percentage viability 
between tumor tissue obtained following surgical 
resection (11–57.9%) and a sample from the same 
tumor cultured in the microfluidic device (17.1–
40.4%) for 48 h was observed using trypan blue exclu-
sion (Figure 4A; n = 15). The viable number of cells 
obtained per milligram of tissue was also calculated, 
with tissue dissociated immediately yielding an average 
of 5.71 × 104 ± 3.14 × 104 viable cells/mg tissue, and 
that dissociated following 48 h of microfluidic culture 
yielding 4.36 × 104 ± 1.63 × 104 viable cells/mg tis-
sue, again with no significant difference between the 
two conditions. For comparison, flow cytometry was 
utilized to quantify cell death by PI staining; again 
no significant difference in percentage cell death was 
observed between the dissociated tumor cells before 
and after 48-h microfluidic culture (Figure 4B; n = 8). 
The viability (by trypan blue) and cell death (as mea-
sured by PI staining) results were concordant.
Tumor cell proliferation
A variation in proliferative capacity of the dissoci-
ated tumor cells was observed between samples with 
formazan product absorbance (492 nm) values rang-
ing from 0.026 to 0.140 in preculture samples and that 
from post-48-h culture samples being 0.022–0.164 
(per milligram of tissue). Consequently, no signifi-
cant difference in proliferation of the cell suspensions 
was observed between pre- and post-48-h culture 
(Figure 4C; n = 7).
Device modeling
The experimental cell configuration is not axisym-
metric, but symmetric along the central plane. This 
plane, which crosses the input–output channel along 
the middle line, is the most information-rich area, 
and provides the flow pattern, characterized by high-
est reynolds number variability. Thus, based on the 
assumption, that further developing of the model 
to 3D would not contribute significantly to the flow 
profile investigation, and would greatly increase sim-
ulation time, the decision was made to apply the 2D 
model to the study. This model allows investigation of 
the main issue of the study: the flow uniformity.
In the first instance, the ‘perfect’ flow simulation 
was modeled that is where the placement of the tissue 
sample within the device was central with no deforma-
tion to the shape of the tissue apparent as a result of the 
force exerted by the flow (Figure 5).
As the structure, shape and the placement of the 
sample within the chamber of the device could all be 
changed as a result of the flow forces acting on the tis-
sue. The device was modeled with a tilt of 5 and 10° 
to show the change to the fluid flow in this situation 
(Figure 6; 10° model).
In order to quantify the flow characteristics, numer-
ically five points around the tissue were chosen for fur-
Figure 2. Photographs of microfluidic culture device and setup. (A) Device close up including PEEK plastic 
microport and PDMS-filled PEEK-threaded adaptor. Connected to inlet and outlet ETFE tubing via graphite 
ferrules. (B) Complete culture setup with syringes containing complete medium attached to a pressure-driven 
syringe pump for continuous flow to the tissue sample within the device. Effluent was collected in Eppendorf 
tubes and the devices were maintained in an incubator at 37°C. 
ETFE: Ethylene tetrafluoroethylene; PDMS: Polydimethylsiloxane; PEEK: Polyether ether ketone.
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ther study (Figure 7A). Point 3 was placed 0.1 mm away 
from the tissue boundary while points 1, 2, 4 and 5 
were placed 0.25 mm away from the tissue boundary 
in all tilt conditions (except in the case of point 4 in 
the 10° tilt analysis where the distance was 0.09 mm). 
Calculated values for Reynolds number and velocity 
magnitude are shown (Table 2).
The Reynolds numbers obtained show values’ char-
acteristic of laminar flow at the 0, 5 and 10° tilt condi-
tions. Velocity magnitude data shows key differences 
within the fluid flow at point 4 in the tilted 10° condi-
tion, given the reduced distance between the tissue and 
the chamber wall the velocity magnitude was increased 
by over 2.5× compared with the 0° initial, no tilt con-
dition. Furthermore, the velocity magnitude at point 4 
was 5.3× higher than that at point 2 in the 10° tilt con-
dition, whereas in the 0° tilt condition point 4 veloc-
ity was only 1.26× higher than point 2. Differences in 
velocity at all other points were minimal.
Discussion
The biological data yielded promising results in terms 
of viability maintenance following microfluidic cul-
ture; intact morphology following microfluidic culture 
was demonstrated by H&E staining with the presence 
of distinct characteristics of squamous cell carcinoma. 
This is in agreement with previous studies from the 
group, using both rat liver and HNSCC tissue [38,39] 
and those of others who used H&E to demonstrate 
maintenance of tissue-specific structures including 
single hair follicular units and human adipose tis-
sue [32,34] with culture times in microfluidic devices 
ranging from 1 to 14 days.
The use of enzymatic and mechanical tissue disso-
ciation to obtain a single cell suspension for subsequent 
analysis allows a more precise determination of cell 
viability and increases the scope of analytical methods 
that are achievable; however, it may also increase the 
chance of experimental-induced damage. The results 
obtained from single cell suspensions showed con-
cordance between trypan blue exclusion and PI flow 
cytometry. Previously, the use of flow cytometry fol-
lowing microfluidic culture has received little attention 
and has only been utilized on prostate and ovarian can-
cer xenograft tissues [31]. In that study, the maintenance 
of small microdissected tissues (MDTs; 380 μM diam-
eter and 300 μM height) was maintained in a micro-
fluidic device with periodic media changes, continuous 
perfusion was not employed. MDTs were stained with 
annexin V and 7AAD prior to dissociation (0.25 mg/
ml collagenase IV in saline 15 min at 37°C) followed by 
flow cytometric analysis. A minimum of 40% viability 
(shown by unstained cells) for 8 days across four differ-
ent xenografts was obtained. Results presented in the 
current study, using PI to assess cell death, detail the 
first flow cytometry data on human primary tissue fol-
lowing microfluidic culture, and showed no increase in 
cell death following the 48-h culture period, although 
the data reveal lower viabilities (preculture average: 
28.9%, post-48-h culture average: 28.1%) than the 
40% reported previously [31]. This could be attribut-
able to the difference in starting material (xenograft vs 
primary tissue) and the experimental procedure differ-
ences, particularly staining the tissue with flow cytom-
etry markers before or after dissociation. Other work 
maintaining HNSCC in microfluidic devices showed 
no significant difference in apoptotic cell death (apop-
totic index, m30 immunohistochemistry [IHC] stain-
ing) between preculture and post-4-day culture, again 
indicating maintenance of tissue [33]; however, samples 
were not disaggregated for cellular analysis.
The range of viable cells/mg obtained experimen-
tally from HNSCC tumors before (1.5 × 104–1.4 
Figure 3. Hematoxylin and Eosin-stained 8-μm tissue 
sections, shown at 100× and 400× magnification. Two 
representative tumors are shown (n = 15). (A) Laryngeal 
squamous cell carcinoma, staging T4aN0M0. (B) 
Transglottic laryngeal squamous cell carcinoma, staging 
T4N0M0. Each tumor is shown pre- and post-48-h 
microfluidic culture. The bright pink-stained areas on 
some of the images depict extracellular keratin (keratin 
pearls*), arising from the squamous cells. White arrows 
show infiltrating islands and cords of tumor cells. Tumor 
area showing orientation of cell maturation is circled 
in white. Pale stromal areas with inflammatory cells are 
circled in yellow. Intact basement membrane is shown 
by yellow arrows.
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× 105) and after 48-h microfluidic culture (1.9–7.6 × 
104) demonstrated no significant effect of microflu-
idic culture on the number of viable cells within the 
tumor tissue. Trypan blue exclusion has previously 
been used following combined mechanical and enzy-
matic dissociation methods (tissue minced, incubated 
4°C with 0.5% trypsin 12–20 h, then agitated with 
rotating razor blades for 5–15 min) on solid tumors’ 
(small-cell lung carcinomas and testicular cancer) pre-
culture yielding 1.5–5 × 104 viable cells/mg [40], thus 
our experimental system appears to extend the range 
from that previously reported.
The current study showed no significant difference 
between the average proliferation of HNSCC samples 
preculture and post-48-h microfluidic culture by the 
MTS proliferation assay, as the variance in the results 
observed was high (0.026–0.146 and 0.022–0.164, 
respectively, absorbance
492nm
/mg tissue). The range in 
proliferation is a relevant observation from the data 
and correlates with the known intertumor heteroge-
neity affecting key cancer pathways driving pheno-
typic variation [41]. Proliferation of HNSCC is known 
to vary between anatomical subsites, for example, 
Pedicini et al., correlated EGFR expression of patient 
tumors to HNSCC subsites with high-EGFR expres-
sion associated with greater proliferation following 
irradiation [42]. Further variation is also seen within 
tumors, (intraheterogeneity: [41,43,44]) which could in 
part explain the variation seen between the precul-
ture and post-48-h microfluidic culture conditions. 
The use of other metabolic activity assays, similar to 
MTS, as a surrogate for proliferation has been used by 
Table 2. Velocity magnitude of fluid flow around the sample with different displacement angles (0, 
5 and 10°) and Reynolds number within the device.
Angle of tilt 
(degrees) 
Velocity magnitude (mm/s)
Point 1 Point 2 Point 3 Point 4 Point 5 
0 0.2 0.19 0.04 0.24 0.24
5 0.19 0.17 0.039 0.26 0.26
10 0.16 0.12 0.039 0.64 0.3
Reynolds number
0 1.9 × 10-3 1.3 × 10-3 4.4 × 10-4 1.5 × 10-3 2.2 × 10-3
5 9.4 × 10-4 6.0 × 10-4 1.4 × 10-4 1.0 × 10-3 1.4 × 10-3
10 1.6 × 10-3 1.3 × 10-3 3.4 × 10-4 5.1 × 10-3 3.1 × 10-3
Point locations are shown Figure 7.
Figure 4. Viability, cell death and proliferation analysis of single cell suspensions from dispersed tumor tissue 
before and after microfluidic culture. (A) Percentage viability of cell population by trypan blue exclusion (n = 15). 
(B) Percentage cell death by PI staining and flow cytometry from 10,000 events (n = 8). (C) Proliferation (MTS 
assay) of cell suspensions following overnight culture quantified by absorbance of colored formazan product at 
492 nm and normalized per milligram of tissue (n = 7). Mean + SEM. 
PI: Propidium iodide.
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others (MTT assay); to compare human adipose tis-
sue before and after 7 days of culture in a microfluidic 
device again with no difference in absorbance observed 
between the preculture and following microfluidic 
 culture conditions [32].
Maintenance of patient tissue on a chip is an emerg-
ing technology with cell culture or ‘engineered tissue’ 
culture on a chip more widely employed; in part due 
to the relative simplicity of sample acquisition and 
availability. However, the use of cell lines, spheroids 
and engineered tissue will always simplify the clinical 
situation and as such often extend culture periods. For 
example, spheroids created from a breast cancer cell line 
or a breast cancer cell line coculture with a fibroblast cell 
line were maintained for up to 14 days shown using Cal-
cein AM (AM; acetoxymethyl ester group) as a viability 
marker [48]. Utilizing primary tissue samples as an alter-
native holds key benefits in the translational relevance 
and application of the data obtained from the devices to 
real-world problems, such as treatment resistance.
The use of modeling to better understand the flow 
patterns within microfluidic devices can aid under-
standing and interpretation of experimental observa-
tions and results; this extra dimension provides infor-
mation regarding the surrounding environment of the 
tissue sample. Furthermore, the modeling can be used 
as a tool to improve the design of devices in order to 
enhance the functionality of the device and/or mimic 
the in vivo situation. The Reynolds number obtained 
for the device in the current study indicates that the 
flow within the channels is ‘creeping flow’ also known 
as the Stokes law region (Reynolds number <1 [49]), 
where the viscous forces of the fluid dominate over the 
inertial forces, due to the low fluid velocities [50]. Thus, 
the flow within the device can be classified as lami-
nar, a key property in the employment of microfluidic 
devices in biomedical applications.
Although this laminar flow in the current device has 
been utilized successfully to maintain HNSCC tissue, 
the modeling has identified some areas for improve-
ment, namely the stagnant flow areas around the base 
of the tissue within the chamber; these areas result in 
reduced perfusion of the tissue. Moreover, it could not 
be excluded that at higher mass inflow the sample would 
Figure 5. Computer simulation of fluid flow and velocity field in the microfluidic culture device. (A) Streamlines 
and velocity vectors of laminar fluid flow in the device. Labels show inlet, outlet and tissue sample location. 
(B) Velocity magnitude of the flow within the device. Color legend explains value of the velocity along the channel 
and the treatment chamber (m/s); thus, the maximum of the velocity equals 1.5 × 10-3 m/s or 1.5 mm/s.
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not touch the chamber walls due to flow pressure, so this 
positioning of the tissue would form a turbulent flow 
pattern with vorticities and zones with velocities close 
to zero. Device modeling has been utilized previously 
to develop designs that allow manipulation of differ-
ent experimental conditions; for example, mathemati-
cal modeling described fluid dynamics alongside intra-
cellular signaling as a key predictor in glucose uptake in 
adipose tissue [32] and assessment of oxygen delivery to 
tumor samples within a microfluidic device [31].
Conclusion
Microfluidic culture successfully maintains HNSCC 
samples for 48 h such that they are comparable to the 
preculture sample in terms of morphology and viability 
with expected variation between patients. The study 
provides scope for extending this time period in future 
work. The current microfluidic device design facili-
tated laminar flow, however, the design also resulted 
in some ‘dead zones’ where the fluid velocity was virtu-
ally nonexistent resulting in limited perfusion. Despite 
this, the maintenance of the tissue viability within the 
microfluidic device is encouraging and invites subse-
quent studies applying treatment regimens to HNSCC 
samples within optimized on-chip devices.
Future perspective
Treatment resistance is a persistent problem yielding 
a worse prognosis and reducing clinical success for 
patients [51]. The selection of a treatment for an individ-
ual patient based on the responsiveness of their malig-
nancy to therapeutic assault could customize care and 
improve outcomes. Culture of small HNSCC samples 
using microfluidic culture as described or in fact the 
culture of any solid tumor could facilitate such testing, 
including that of novel agents. Additionally, modifica-
tions in device design guided by CFD could improve 
perfusion to the whole surface of the tissue and as such 
increase the length of the culture period. Future work 
on treatment application to these devices will increase 
the translational relevance of the technology allowing 
monitoring of patient-specific tumors and their response 
to therapeutic assault, in order to direct treatment 
 decision-making.
Figure 6. Computer simulation of fluid flow in the microfluidic tissue culture device, with tissue sample tilted 
10° due to the flow pressure. (A) Streamlines and velocity vectors of laminar fluid flow in the device. Labels 
show inlet, outlet and tissue sample location. (B) Velocity magnitude of the flow within the device. Color legend 
explains value of the velocity along the channel and the treatment chamber (m/s); thus, the maximum of the 
velocity equals 1.5 × 10-3 m/s or 1.5 mm/s.
0
-1
1
-2
4
3
2
0 10 15 205
mm
m
m
Outlet
Tissue
sample
Inlet
0
-1
1
4
3
2
0
0.0 0.5 1.0 1.5
10 15 205
mm
m
m
× 10-3 (m/s)
Future Sci. OA (2017), 3(2), FSO174 www.future-science.com 10.4155/fsoa-2016-0089future science group
Maintenance of head & neck tumor on-chip: gateway to personalized treatment?    Research Article
Supplementary data
To view  the  supplementary data  that accompany  this paper 
please  visit  the  journal website  at: www.future-science/doi/
full/10.2217/fsoa-2016-0089
Author contributions
R Bower, V Green and J Greenman were involved in the design 
of the experiments, interpretation of the data and writing the 
article. E Kuvshinova, D Kuvshinov and R Bower were involved 
in  computational  fluid  dynamics,  interpretation  of  the  out-
put and writing the relevant sections. L Karsai  reviewed the 
histology  sections and was  involved  in  the analysis of  these 
data. S Crank and N Stafford collected HNSCC specimens. All 
 authors approved the final version of the manuscript.
Acknowledgements
The authors would  like  to acknowledge the patients of Hull 
and East Yorkshire NHS Trust who allowed samples to be used 
in this research and the assistance of Jemy Jose alongside the 
ENT and Oral & Maxillofacial theatre teams for the sample col-
lection. R Bower received a PhD studentship from the Univer-
sity of Hull Brignall Scholarship, without this the work herein 
would not have been possible.
Financial & competing interests disclosure
The authors have no relevant affiliations or financial involve-
ment with  any  organization  or  entity with  a  financial  inter-
est  in  or  financial  conflict with  the  subject matter  or mate-
rials discussed  in the manuscript. This  includes employment, 
consultancies, honoraria, stock ownership or options, expert 
testimony, grants or patents received or pending, or royalties.
No writing assistance was utilized in the production of this 
manuscript.
Open access
This work is licensed under the Creative Commons Attribution 
4.0 License. To view a copy of this license, visit http://creative-
commons.org/licenses/by/4.0/
Executive summary
•	 Head and Neck Squamous Cell Carcinomascan be maintained in our tumor-on-chip device without loss of 
sample viability for 48 h.
•	 Squamous cell carcinoma tissue morphology characteristics are maintained following culture.
•	 Computational fluid dynamics alongside biological data is valuable in terms of characterizing the sample 
environment and improving the model system.
•	 Establishment of an optimized, defined, model system will allow tissue to be tested for response to different 
treatment modalities simultaneously.
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